FOR YOUR PATIENTS

Dr. Sharon Jacob

Director, Contact Dermatitis Clinic of the University of Miami-Miller School of Medicine and Assistant Professor, Clinical Dermatology, Department of Dermatology and Cutaneous Surgery; President, Florida Contact Dermatitis Society and a consultant for Shire US Inc.

TREAT ME LIKE ME…

Day-Long Control that Lasts Into the Evening

A key benefit of Daytrana is day-long control of ADHD symptoms that lasts into the evening. Daytrana provides significant symptom control of behavior at all time points measured through 12 hours when the patch is worn for 9 hours.

SKAMP* Deportment: mean change from predose (measured 2-12 hours)⁴

SKAMP*-Deportment: mean change from baseline (measured 2-12 hours)

Randomized double-blind placebo-controlled analog classroom study of 93 subjects aged 6 to 12 years who met DSM-IV TR^† criteria for a primary diagnosis of ADHD³
The majority of subjects were categorized as moderately (55.9%) or markedly (34.4%) ill⁵
Data from the laboratory classroom study demonstrated that the mean change from baseline (measured 2-12 hours)⁴ in SKAMP deportment scores was statistically significant (P < .001) in favor of Daytrana versus placebo. Daytrana provided significant improvement in behavior such as remaining quiet or staying seated at all the measured time points through 12 hours when the patch was worn for 9 hours¹
Consistent with adverse events (AEs) commonly associated with the use of MPH, common AEs reported by patients who received Daytrana in 2 pivotal trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, anorexia, and headache^1,⁶

Continuous Delivery for Smooth Levels of Medication Throughout Long School Days

Mean plasma concentration of d-MPH²

Lower limit of quantification (0.25 ng/mL).
Study 201: Drug concentration from multiple-dose administration of Daytrana in a randomized, double-blind, placebo-controlled laboratory classroom study.

Ascending plasma concentration curve results from continuous delivery of MPH^2,⁹
Even though every patient is different, physicians can have confidence that Daytrana delivers MPH continuously for as long as the patch is worn^1,2,⁹

Significant Improvement in Math Test Performance

PERMP^‡: mean change from predose in number of math problems correct⁴

Study 201: Randomized, double-blind, placebo-controlled analog classroom study of 93 subjects aged 6 to 12 years, who met DSM-IV-TR^® criteria for a primary diagnosis of ADHD.³ The majority of subjects were categorized as moderately (55.9%) or markedly (34.4%) ill on the CGI-S.⁵

In a laboratory classroom study, Daytrana significantly improved children's math test performance as measured on the PERMP Scale³
Clinicians witnessed significant improvement based on CGI-I^§ ratings³

Efficacy That Adds Up To Success

Daytrana delivered effective symptom control, from improvement in behavior and attention to increased performance on math tests.^1,3

*SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham.
†Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. DSM-IV-TR^® is a registered trademark of the American Psychiatric Association.
‡Permanent Product Measure of Performance.
^§Clinical Global Impressions-Improvement.

NEXT ARTICLE…

What Is the Safety Profile?



Developed under the direction and sponsorship of Shire Pharmaceuticals. Contains promotional material.